187 related articles for article (PubMed ID: 34320663)
1. Hypoxia-inducible Factor 2α: A Key Player in Tumorigenesis and Metastasis of Pheochromocytoma and Paraganglioma?
Bechmann N; Eisenhofer G
Exp Clin Endocrinol Diabetes; 2022 May; 130(5):282-289. PubMed ID: 34320663
[TBL] [Abstract][Full Text] [Related]
2. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
3. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
4. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
[TBL] [Abstract][Full Text] [Related]
5. Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.
Richter S; Qin N; Pacak K; Eisenhofer G
Adv Pharmacol; 2013; 68():285-317. PubMed ID: 24054150
[TBL] [Abstract][Full Text] [Related]
6. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
7. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
8. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
[TBL] [Abstract][Full Text] [Related]
9. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
10. Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas.
Jones RB; Cohen DL
Curr Cardiol Rep; 2023 Nov; 25(11):1451-1460. PubMed ID: 37847359
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
12. Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells.
Bechmann N; Poser I; Seifert V; Greunke C; Ullrich M; Qin N; Walch A; Peitzsch M; Robledo M; Pacak K; Pietzsch J; Richter S; Eisenhofer G
Cancers (Basel); 2019 Apr; 11(5):. PubMed ID: 31035382
[TBL] [Abstract][Full Text] [Related]
13. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
Jochmanová I; Yang C; Zhuang Z; Pacak K
J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
[TBL] [Abstract][Full Text] [Related]
16. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model.
Helm J; Drukewitz S; Poser I; Richter S; Friedemann M; William D; Mohr H; Nölting S; Robledo M; Bornstein SR; Eisenhofer G; Bechmann N
Cells; 2022 Feb; 11(3):. PubMed ID: 35159368
[TBL] [Abstract][Full Text] [Related]
18. PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.
Gupta G; Pacak K;
Endocr Pract; 2017 Jun; 23(6):690-704. PubMed ID: 28332883
[TBL] [Abstract][Full Text] [Related]
19. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
[TBL] [Abstract][Full Text] [Related]
20. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population.
Choi H; Kim KJ; Hong N; Shin S; Choi JR; Kang SW; Lee ST; Rhee Y
Endocrinol Metab (Seoul); 2020 Dec; 35(4):858-872. PubMed ID: 33397040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
